Relationship Between Decrease in Ambulatory Blood Pressure and Heart Rate Variability Due to the Effects of Taking Olmesartan Medoxomil
Tóm tắt
Background and methods: A higher degree of clinical efficacy with olmesartan compared with other angiotensin receptor blockers, has been reported by several sources. In this study of 31 examples of cases of essential hypertension, Holter electrocardiogram, ambulatory blood pressure monitoring and pulse wave velocity (PWV) measurements were performed before and after substituting olmesartan 20 mg for candesartan 8 mg antihypertensive drug therapy.
Results: Following the therapeutic change, daily average systolic and diastolic blood pressures were decreased by 6.7 ± 9.3 mmHg and 3.6 ± 8.3 mmHg, respectively, with olmesartan 20 mg; PWV was also significantly decreased. Holter electrocardiogram heart rate variability spectral analysis demonstrated that none of the very low frequency (VLF), high frequency (HF) and low frequency (LF)/HF components were significantly altered. However, a significant correlation was observed between the LF/HF component and blood pressure difference, when blood pressure and heart rate variability components in each individual case were studied.
Conclusion: This study shows that olmesartan has a stronger antihypertensive effect in comparison to candesartan, and does not generate reflex sympathoexcitatory activity.
Tài liệu tham khảo
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215): 1582–7
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667–75
Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759–66
Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26Suppl. A: A33–7
Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26(4): 185–93
Hiromichi S. Examination of the clinical usefulness of various angiotensin receptor blockers in regard to treatment of hypertension that accompanies nephropathy. Prog Med 2006; 26: 1669–75
Taiji S, Misako T, Tatsuya O, et al. Examination with regard to the effects of olmesartan on hypertension patients with diabetic complications. Prog Med 2006; 26: 475–9
Shinji T, Masato O, Satoshi M, et al. Blood pressure survey of essential hypertension patients in the early morning, ambulatory period and at night: ATOM Research. Pharmacol Treat 2004; 32: 481–6
Mitera T, Saitou M, Satou T, et al. 24-hour blood pressure and time course of heart rate variability changes in regard to 3 kinds of dihydropyridine-type Ca2+ channel blockers. Electrocardiogram 2001; 21: 481–90
Keishi A, Iwao K, Yutaka I, et al. Effects of the long-acting type Ca blocker balnidipine hydrochloride on blood pressure circadian rhythm: large-scale clinical trial J-MUBA. Final results. Ther Res 1999; 20: 2697–713
Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6(10): 569–77
Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3(5): 283–91, 318
Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other anti-hypertensive agents: olmesartan medoxomil versus anti-hypertensives. J Hypertens Suppl. 2001; 19(1): S49–56
Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115–21
Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92(5): 1326–31
Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39(1): 10–5
Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34(5): 1203–6